Health Condition 1: null- Genital warts
Conditions
Interventions
Intervention1: Biopsy: The clinically diagnosed patients of genital warts will be subjected for a biopsy of the warts to confirm the histopath diagnosis
Control Intervention1: Nil: Nil
Sponsors
MSD Pharmaceuticals Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients between the age group of 18-45 years 2. Clinically and pathologically confirmed cases of genital warts 3. Able to give a written informed consent 4. Able to provide responses to the questionnaire used in this study
Exclusion criteria
Exclusion criteria: Patients showing evidence of neoplasia or invasive cancer 2. Patients who are commercial sex workers 3. Patients diagnosed with active cervical disease 4. Female patients who had undergone genital tract surgery 5. Patients who have received previous treatment for current episode of genital warts 6. Patients who have enrolled in any other clinical trial for management of genital warts during the past 6 months 7. Patients with signs of secondary infection or discharge from the site of warts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of HPV type 6 and type 11 in patients of genital warts.Timepoint: Prevalence of HPV type 6 and type 11 in patients of genital warts. | — |
Secondary
| Measure | Time frame |
|---|---|
| Estimation of management cost of genital warts: Includes direct medical costs and direct non-medical costs (sundry expenses, lost salary etc) based on investigatorâ??s evaluation of patientâ??s disease condition at enrollment. Timepoint: 9 months;Psychological impact of genital warts: A one-to-one standardized HIP (Human Papilloma Virus Impact Profile) questionnaire will be used.Timepoint: 9 months | — |
Countries
India
Contacts
Public ContactNarendra Patil
MSD Pharmaceuticals
Outcome results
None listed